How Are Vaccines Administered: Methods and The Process

Most vaccines reach your body through a needle inserted into muscle, but that familiar jab is only one of several delivery methods, and the specific route, needle size, injection site, and technique all influence how well the vaccine works and how you feel afterward. Intramuscular injection dominates modern vaccination schedules, yet subcutaneous shots, intradermal techniques, oral drops, nasal sprays, and emerging needle-free technologies each serve distinct purposes. The process involves more deliberate decision-making than most people realize, from choosing the right spot on your body to selecting a needle length matched to your build.

Intramuscular Injection and Why It Is the Default

The vast majority of vaccines you encounter in a clinic or pharmacy are given as intramuscular (IM) injections. The deltoid muscle of your upper arm is the standard site for adults and older children, while infants typically receive shots in the vastus lateralis, the large muscle on the outer thigh. The middle portion of the vastus lateralis is favored in infants and young children because it carries a low risk of hitting a nerve or blood vessel.¹

Muscle tissue has a rich blood supply and contains resident immune cells that efficiently pick up vaccine antigens and carry them to nearby lymph nodes. That combination of good blood flow and rapid immune-cell access is a big part of why IM injection produces strong, reliable immune responses for most vaccines. The tissue also absorbs the injected fluid steadily, which helps avoid the lingering lumps or nodules that can form when vaccine material pools in fat or just under the skin.

Subcutaneous and Intradermal Routes

Subcutaneous (SC) injections deliver vaccine into the fatty tissue just beneath the skin, usually in the upper arm or thigh. A few live-virus vaccines were historically developed and tested using the SC route. The shingles vaccine Zostavax, for instance, was administered subcutaneously during its original clinical development.² However, a review of seventeen studies comparing IM with SC delivery of live-virus vaccines found that SC injection caused higher rates of local reactions, such as redness, swelling, and pain, in thirteen out of fifteen studies that tracked those outcomes. Immune responses were comparable between the two routes in nearly all the trials, but the local-reaction gap has pushed many guidelines to favor IM injection even for vaccines that can technically be given subcutaneously.³

Intradermal (ID) injection targets the dermis, the thin layer of skin sitting just above the subcutaneous fat. The dermis is packed with specialized immune cells, including Langerhans cells and dermal dendritic cells, which are exceptionally good at capturing antigens and launching an immune response. Because this layer is so immunologically active, intradermal vaccination can achieve comparable immune responses with a fraction of the dose needed for an intramuscular shot.⁴ That dose-sparing capability becomes especially important during pandemics or other supply shortages, when stretching limited vaccine stocks across more people can save lives. The downside is that ID injection requires more skill; the needle must enter at a very shallow angle and deposit the liquid in a precise tissue layer, which makes it harder to administer quickly in a mass-vaccination setting.

Oral and Nasal Vaccines

Not all vaccines arrive through a needle. Oral polio vaccine, the rotavirus vaccine given to infants, and certain cholera vaccines are swallowed as drops or liquid solutions. Nasal spray vaccines, like the live attenuated influenza vaccine (commonly known by the brand FluMist), are spritzed into the nostrils. These mucosal routes work by stimulating immune defenses right at the surfaces where many pathogens first enter the body.

When a vaccine is delivered to mucosal tissue in the nose or gut, it triggers the production of secretory IgA antibodies, a class of antibody specifically adapted to patrol mucosal surfaces. These antibodies can intercept a pathogen before it establishes infection, which is something injectable vaccines are less efficient at doing. At mucosal sites, immune cells activate pathways that lead to IgA class switching, where B cells become specialized producers of these surface-guarding antibodies.⁵ For respiratory viruses, the appeal of nasal vaccines is that they could potentially block transmission at the point of entry, rather than only preventing severe disease once the virus has already gotten deeper into the body.⁶

The practical advantages of mucosal vaccines are significant, too. No needles means no sharps waste, no trained injector needed, and less anxiety for people who fear needles. That makes oral and nasal vaccines especially well-suited for mass campaigns in low-resource settings or for children.

Why Needle Length and Injection Site Matter

Getting the needle into the right tissue layer sounds simple, but body composition makes it more complicated than you might expect. For IM vaccination in the deltoid, the needle has to pass through skin and the subcutaneous fat pad before reaching muscle. A study measuring deltoid fat thickness across different body types found that a standard one-inch needle reaches the deltoid muscle in about 85% of women under 200 pounds and roughly 99% of men under 260 pounds. For people above those weight thresholds, the odds of the vaccine landing in subcutaneous fat instead of muscle were more than four times higher when using the standard recommended needle length.⁷

When a vaccine intended for muscle ends up in fat, the immune response can be weaker, and local reactions like pain and swelling tend to be worse. This is one of the practical reasons your vaccinator might size you up before choosing a needle. Guidelines generally call for a longer needle (typically 1.5 inches) in larger adults, but the research suggests that even with longer needles, a meaningful fraction of above-threshold individuals may still get an inadvertent subcutaneous injection. For most people the system works well, but it is far from a one-size-fits-all process.

Clinical Technique and the Aspiration Debate

If you have ever watched someone give an injection, you might have noticed them pull back on the plunger briefly before pushing the vaccine in. That step, called aspiration, was traditionally taught as a way to check whether the needle had accidentally entered a blood vessel. But a meta-analysis of studies examining this practice found that aspiration during IM injections increases pain and extends the procedure without reducing the risk of complications.⁸ International guidelines now discourage routine aspiration for vaccine injections, especially in children. At common vaccine injection sites like the deltoid and the vastus lateralis, there are no large blood vessels that the needle is likely to hit, so the theoretical safety benefit never materialized in real-world data.

Other technique details also affect your experience. Injecting the most painful vaccine last when giving multiple shots in a single visit, delivering vaccines simultaneously rather than one at a time, and choosing the thigh over the deltoid for infants have all been shown to reduce distress. Skin-to-skin contact for neonates, holding infants during and after the shot, and offering a pacifier (non-nutritive sucking) are all backed by randomized trial evidence as ways to ease infant pain during vaccination.⁹ For older children and adults, sitting upright rather than lying down appears to reduce self-reported fear, and muscle tension exercises can help people prone to fainting.

When Administration Goes Wrong

The most well-known injection-related complication is shoulder injury related to vaccine administration, known by the acronym SIRVA. This happens when the needle is inserted too high on the arm, allowing vaccine material to enter structures like the subdeltoid bursa rather than the deltoid muscle itself. The resulting inflammation can cause persistent shoulder pain and restricted range of motion that lasts weeks or months.¹⁰

The subdeltoid bursa sits only about 3 to 6 centimeters below the bony point of the shoulder (the acromion), and its depth from the skin surface can be as little as 0.8 centimeters. Even a standard-length needle can reach it if the injection is placed too close to the shoulder joint. Because the subdeltoid and subacromial bursas are connected, inflammation from a misplaced injection can spread and involve nearby tendons and the joint capsule.¹¹ SIRVA is preventable through proper landmark identification. The injection should target the thickest part of the deltoid, roughly two to three finger-widths below the acromion, not at the very top of the shoulder.

Anaphylaxis is the acute reaction people worry about most, but it remains genuinely rare. Surveillance of the Moderna COVID-19 vaccine after its initial rollout found roughly 2.5 cases of anaphylaxis per million doses administered. The median time from injection to symptom onset was about seven and a half minutes, and among cases with follow-up data, all recovered.¹² The standard 15-minute post-vaccination observation period exists precisely because most anaphylactic reactions appear within that window.

Common Side Effects and What Drives Them

Soreness, redness, and swelling at the injection site are so common that they have their own clinical category: local reactogenicity. These reactions stem from the inflammatory response your immune system mounts against the vaccine antigens and any adjuvants (immune-boosting additives) in the formula. Systemic reactions like fever, fatigue, muscle aches, and headache also reflect your immune system ramping up.¹³ These are not signs that something went wrong; they are signs that something went right, specifically that your innate immune system recognized the vaccine as foreign and is processing it.

The route of administration can influence the pattern of side effects. As mentioned earlier, subcutaneous injection tends to produce more local reactions than intramuscular injection for many vaccines. Intradermal delivery often causes a visible wheal and local redness that can look alarming but is expected. Oral and nasal vaccines tend to avoid injection-site pain entirely, though they can cause their own mucosal symptoms like a runny nose or mild sore throat.

Microneedle Patches and the Future of Needle-Free Delivery

Perhaps the most promising alternative to conventional needles is the dissolving microneedle patch, a small adhesive patch studded with tiny projections barely visible to the naked eye. Each microneedle is just long enough to penetrate the outermost skin layers and dissolve within minutes, releasing vaccine directly into the dermis, where it encounters those densely packed immune cells.¹⁴ Because the needles dissolve completely, there is no sharps waste and no risk of needle-stick injuries.

One of the biggest practical advantages is thermal stability. Conventional vaccines require continuous refrigeration from the factory to the clinic, a logistics chain that is difficult and expensive to maintain in tropical climates and remote areas. In testing, influenza vaccine formulated in microneedle patches retained full activity after storage at room temperature for up to two years. The best formulations showed no significant loss even after four months at 60°C, or after repeated freeze-thaw cycles.¹⁵ Polio vaccine in microneedle patches also showed improved stability compared to the liquid form, maintaining more than 70% activity after two months at room temperature while the conventional liquid version lost nearly all activity within a month at elevated temperatures.¹⁶

Jet injectors represent another needle-free approach. These devices use a high-speed, narrow stream of liquid to punch through the skin without a conventional needle. They produce immune responses that are comparable to or better than standard needle-and-syringe delivery.¹⁷ Newer designs use compressed air to control delivery depth, allowing the same device to target the dermis, subcutaneous tissue, or muscle depending on the pressure setting.¹⁸ Jet injectors have been used in military settings and mass campaigns, though concerns about potential cross-contamination between patients with earlier multi-use models limited their adoption. Modern single-use-cartridge designs have addressed that issue.

How mRNA Vaccines Changed the Delivery Conversation

The COVID-19 pandemic brought mRNA vaccines into the mainstream, and with them came a delivery vehicle that was new to most people: lipid nanoparticles. These tiny fat-based capsules protect the fragile mRNA and shuttle it into cells at the injection site. For vaccination purposes, IM, SC, and intradermal injection all work in principle because resident and recruited antigen-presenting cells in skin and muscle can take up the nanoparticles, process the mRNA-encoded antigen, and carry it to draining lymph nodes to activate T cells.¹⁹ The choice of IM injection for the authorized COVID-19 vaccines was driven largely by practicality and the clinical trial data available, but research into intradermal mRNA delivery continues because of its dose-sparing potential.

Self-Administration on the Horizon

Could you vaccinate yourself at home? For certain delivery formats, the answer is already yes. Trials of self-administered intranasal influenza vaccine in military populations found that safety and immune responses were equivalent whether the vaccine was given by a health care worker or by the volunteers themselves. About 97% of self-administrators had no problems with the process.²⁰ A separate randomized trial confirmed those findings, showing that self-administered nasal flu vaccine was non-inferior to the health-care-worker-administered version on both safety and immunogenicity measures.²¹

Microneedle patches push self-administration even further. A preliminary study in adults aged 50 and older found that self-applied patches engaged the skin comparably to patches applied by trained users, and all participants rated the applicator as easy to use. There were no treatment-related serious adverse events.²² The implications are substantial: if a shelf-stable patch can be mailed to your home and applied like a bandage, vaccination campaigns could bypass clinics entirely. That would be transformative for rural areas, pandemic surges, and countries without a dense network of trained vaccinators.

Reducing Pain and Fear During Vaccination

Needle phobia is not a trivial barrier. Surveys consistently find that fear of needles is a significant reason some people delay or refuse vaccination, particularly among children and adolescents. A framework called CARD (Comfort, Ask, Relax, Distract) was developed to integrate evidence-based pain and fear reduction into routine vaccination delivery.²³ The idea is straightforward: make the physical environment comfortable, ask the patient about their preferences and coping strategies, encourage relaxation techniques like slow breathing, and use age-appropriate distraction such as conversation, videos, or toys.

On the physical side, combining an external vibrating device with cold applied near the injection site reduced children’s pain substantially in randomized trials. Non-nutritive sucking (a pacifier, essentially) showed the largest effect of any single physical intervention for infants.⁹ Some interventions people assume would help actually do not: warming the vaccine beforehand showed no benefit in adults, and manual rubbing or tapping near the injection site did not reduce pain across any age group. The interventions that work are specific and well-studied, so it is worth asking your provider about them, especially if you are bringing a child in for shots.

How Veterinary and Mass-Scale Campaigns Differ

Human vaccination gets most of the attention, but the logistical challenges of immunizing billions of livestock and poultry have driven some creative approaches. In the poultry industry, live anticoccidial vaccines are delivered through drinking water, spray cabinets, or gel droplets placed in hatchery trays. The critical challenge is not the immune response itself but getting uniform coverage so that every bird ingests enough oocysts for the vaccine to work. The success of these campaigns depends largely on how evenly the vaccine is distributed across the flock. These mass-delivery methods would not be practical for human vaccines with today’s formulations, but the underlying principle of reaching large populations without individual needle injections resonates with the goals driving microneedle patch and nasal vaccine development for people.

Jet injectors have a parallel history in both human and veterinary medicine. In large-scale human campaigns during the mid-twentieth century, jet injectors were used to vaccinate millions of people against smallpox and other diseases quickly. The technology fell out of favor for routine human use but has remained in use in some veterinary and military contexts, and the newest single-dose cartridge designs are making a comeback in human medicine as well.